March 2023

Impact of NSAIDs on 8-year Cumulative Incidence of Major Cardiovascular Events in Patients with Ankylosing Spondylitis: A Nationwide Study

Rheumatology (Oxford). 2023 doi: 10.1093/rheumatology/kead072

MACEs were observed in patients newly receiving compensation from the Long-term Illness Scheme for AS. The objective of this study was to describe the incidence of MACEs in French patients newly benefiting from the French LTI for AS. The study also sought to evaluate the effect of various treatments on the risk of MACE occurrence.

Keywords:

February 2023

Achilles Enthesitis on Physical Examination Leads to Worse Outcomes After 2 Years of Follow up in Patients with Ankylosing Spondylitis From REGISPONSER-AS Registry

Arthritis Res Ther. doi: 10.1186/s13075-023-02988-x

The results highlighted the long-term impact of the presence of Achilles enthesitis on the burden of disease. The objectives of this study were to evaluate the impact of Achilles' tendon enthesitis found at baseline during physical examination on the outcome measures after 2 years of follow-up in patients with AS.

Keywords:

Herpes zoster in Patients with Inflammatory Arthritides or Ulcerative Colitis Treated with Tofacitinib, Baricitinib or Upadacitinib: A Systematic Review of Clinical Trials and Real-world Studies

Overall, this evidence supports that HZ-risk is a “class” effect of JAKi, observing a higher risk compared to other non-biologic/biologic drugs . This study aimed to systematically review the incidence of HZ among RA, PsA, AS and UC patients treated with TOFA, BARI or UPA.

Overall, this evidence supports that HZ-risk is a “class” effect of JAKi, observing a higher risk compared to other non-biologic/biologic drugs . This study aimed to systematically review the incidence of HZ among RA, PsA, AS and UC patients treated with TOFA, BARI or UPA.

Keywords:

December 2022

Treatment Persistence of Tumour Necrosis Factors And IL-17 Inhibitors in Axial Spondyloarthritis: A Multi-Center Comparative Analysis

Joint Bone Spine 2022; 89:105416 doi: 10.1016/j.jbspin.2022.105416

In this multi-centric, real-world study, persistence with secukinumab and TNFi were not statistically different for matched populations. The primary outcome of this analysis was drug persistence, calculated as the difference in months between initiation and discontinuation.

Keywords:

Real-world Treatment Patterns and Use of Adjunctive Pain and Anti-inflammatory Medications Among Patients with Psoriatic Arthritis Treated With IL-17A Inhibitors In The United States

J Manag Care Spec Pharm. 2022 doi: 10.18553/jmcp.2022.22144

In this study ixekizumab and secukinumab patients had similar treatment patterns. It was also surmised that the use of adjunctive pain and anti-inflammatory medications were similar between therapies. In coming to this conclusion investigators aimed to compare treatment patterns and use of pain and anti-inflammatory medications between patients with PsA initiating ixekizumab and secukinumab in two cohorts of patients from…(add here where is the population coming from).

Keywords:

November 2022

Tofacitinib and Risk of Malignancy: Results From the Safety of Tofacitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA) Study

Arthritis Rheumatol. 2022;74:1648–1659 doi: 10.1002/art.42250

Large, population-based, real-world cohort of study in patients with RA finds tofacitinib not to be associated with an increased risk of malignancies, in comparison to TNFi agents, although a numerically increased risk of malignancies was observed in older patients with risk factors for cardiovascular disease.

Keywords:

Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study

Ann Rheum Dis. 2022. doi: 10.1136/ard-2022-222824

Real-world population study of patients with RA provides reassuring data regarding the risks of major adverse cardiovascular events (MACEs) and venous thromboembolism events (VTEs) in patients initiating a JAKinib versus adalimumab, including patients at high risk of cardiovascular diseases.

Keywords:

October 2022

Venous Thromboembolism with JAK Inhibitors and Other Immune-Modulatory Drugs: a Swedish Comparative Safety Study Among Patients with Rheumatoid Arthritis

Ann Rheum Dis. 2022. doi: 10.1136/ard-2022-223050

Nationwide register-based study in Sweden finds that patients with RA treated with JAKinibs in routine clinical practice are at increased risk of venous thromboembolism (VTE), compared with those treated with bDMARDs, an increase numerically confined to pulmonary embolism.

Keywords:

August 2022

Incident and Recurrent Herpes Zoster for First-Line bDMARD and tsDMARD Users in Seropositive Rheumatoid Arthritis Patients: A Nationwide Cohort Study

Arthritis Res Ther. 2022;24(1):180

Herpes zoster (HZ) risk is significantly increased in seropositive RA patients with a history of HZ after the initiation of bDMARDs or tsDMARD. It is now well known that the incidence and recurrence of HZ are quite common in patients with RA in real-world clinical settings, yet there is limited evidence regarding bDMARD-dependent HZ risk among patients with a history of HZ prior to bDMARD use.

Keywords:

June 2022

Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration

Ann Rheum Dis. 2022 doi: 10.1136/annrheumdis-2022-222586

Observational study of data, from large international collective of registers, finds similar overall drug retention rates between RA treatment groups.

Keywords: